1. Parkin D.M., Bray F., Ferlay J., Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108.
2. IARC. <http://www-dep.iarc.fr/&gt;; 2011 [accessed 01.11.11].
3. Sanyal A.J., Yoon S.K., Lencioni R. The Etiology of Hepatocellular Carcinoma and Consequences for treatment. Oncologist 2010; 15 (suppl 4): 14-22.
4. Beasley R.P. Hepatitis B virus. The major etiology of hepatocellular carcinoma. Cancer 1988; 61: 1942-1952.
5. Hassan M.M., Hwang L.Y., Hatten C.J. et al. Risk factors for hepatocellular carcinoma: synergism of alcohol with viral hepatitis and diabetes mellitus. Hepatology 2002; 36: 1206-1213.
6. Franceschi S., Montella M., Polesel J. et al. Hepatitis viruses, alcohol, and tobacco in the etiology of hepatocellular carcinoma in Italy. Cancer Epidemiol Biomarkers Prev 2006; 15 (4): 683-689.
7. Chen C.J., Yang H.I., Su J. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. REVEAL-HBV Study Group. JAMA 2006; 4 (2951): 65-73.
8. Yang H.I., Yuen M.F., Chan H.L. Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score. Lancet Oncol 2011; 12: 568-574.
9. Albanis E., Friedman S.L. Hepatic fibrosis. Pathogenesis and principles of therapy. Clin Liver Dis 2001; 5: 315-334.
10. Gressner O.A., Weiskirchen R., Gressner A.M. Evolving concepts of liver fibrogenesis provide new diagnostic and therapeutic options. Comparative Hepatol 2007; 6: 7-10.
11. Zois C.D., Baltayiannis G.H., Karayiannis P., Tsianos E.V. Systematic review: hepatic fibrosis-regression with therapy. Aliment Pharmacol Ther 2008; 28: 1175-1187.
12. Wege H., Brummendorf T.H. Telomerase activation in liver regeneration and hepatocarcinogenesis: Dr. Jekyll or Mr. Hyde? Curr Stem Cell Res Ther 2007; 2: 31-38.
13. Wiemann S.U., Satyanarayana A., Tsahuridu M. et al. Hepatocyte telomere shortening and senescence are general markers of human liver cirrhosis. FASEB J 2002; 16: 935-942.
14. Carson D.A., Lois A. Cancer progression and p53. Lancet 1995; 346: 1009-1011.
15. Hoshida Y., Villanueva A., Kobayashi M. et al. Gene expression in fixed tissues and outcome in hepatocellular carcinoma. NEJM 2008; 359 (19): 1995-2004.
16. Bedossa P., Poynard T. The French METAVIR Cooperative Study Group. An algorithm for grading activity in chronic hepatitis C. Hepatology 1996; 24: 289-293.
17. Ishak K., Baptista A., Bianchi L. et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22: 696-699.
18. Knodell R.G., Ishak K.G., Black W.C. et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981; 4: 431-435.
19. Castera L., Forns X., Alberti A. Non-invasive evaluation of liver fibrosis using transient elastography. J Hepatol 2008; 48 (5): 835-847.
20. Imbert-Bismut F., Ratziu V., Pieroni L. et al. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet 2001; 357: 1069-1075.
21. Mommeja-Marin H., Mondou E., Blum M.R., Rousseau F. Serum HBV DNA as a marker of efficacy during therapy for chronic 3HBV infection: analysis and review of the literature. Hepatology 2003; 37 (6): 1309-1319.
22. Sung J.J., Tsoi K.K., Wong V.W. et al. Meta-analysis: treatment of hepatitis B infection reduces risk of hepatocellular carcinoma. Aliment Pharmacol Ther 2008; 28: 1067-1077.
23. Lin S.M., Yu M.L., Lee C.M. et al. Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma. J Hepatol 2007; 46 (1): 45-52.
24. Papatheodoridis G.V., Petraki K., Cholongitas E. et al. Impact of interferon-alpha therapy on liver fibrosis progression in patients with HBeAg-negative chronic hepatitis B. J Viral Hepat 2005; 12 (2): 199-206.
25. Liaw Y.F., Sung J.Y., Chow W.C. et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004; 351: 1521-1531.
26. Singal A.K., Salameh H., Kuo Y.F., Fontana R.J. Meta-analysis: the impact of oral anti-viral agents on the incidence of hepatocellular carcinoma in chronic hepatitis B. Aliment Pharmacol Ther 2013; 38 (2): 98-106.
27. Papatheodoridis G.V., Lampertico P., Manolakopoulos S., Lok A. Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic review. J Hepatol 2010; 53 (2): 348-356.
28. Chang T.T., Liaw Y.F., Wu S.S. et al. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology 2010; 52: 886-893.
29. Mochida S., Takaguchi K., Yokosuka O. et al. Long term efficacy, safety and resistance analyses of entecavir treatment in Japanese nucleoside-naive patients with chronic hepatitis B. J Hepatol 2008; 48 (suppl 2): 262.
30. Wong G.L., Chan H.L., Mak C.H. et al. Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis. Hepatology 2013, doi: 10.1002/hep.26301.
31. Hosaka T., Suzuki F., Kobayashi M. et al. Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection. Hepatology 2012, doi: 10.1002/hep.26180.
32. Singal A.K., Singh A., Jaganmohan S. et al. Antiviral therapy reduces risk of hepatocellular carcinoma in patients with hepatitis C virus related cirrhosis. Clin Gastroenterol Hepatol 2010; 8: 192-199.
33. Schvarcz R., Glaumann H., Reichard O., Weiland O. Histological and virological long-term outcome in patients treated with interferon-alpha2b and ribavirin for chronic hepatitis C. J Viral Hepat 1999; 6 (3): 237-242.
34. Bruno S., Stroffolini T., Colombo M. et al. Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study. Hepatology 2007, 45, 579-587.
35. Camm C., Di Bona D., Craxà A. The impact of antiviral treatments on the course of chronic hepatitis C: an evidence-based approach. Curr Pharm Des 2004; 10 (17): 2123-2130.
36. Mallet V., Gilgenkrantz H., Serpaggi J. et al. Brief communication: the relationship of regression of cirrhosis to outcome in chronic hepatitis C. Ann Intern Med 2008; 149 (6): 399-403.

________________________________________________

D.T. ABDURAKHMANOV

Department of Visceral and Occupational Diseases and Pulmonology, I.M. Sechenov First Moscow State Medical University